Followers | 29 |
Posts | 1427 |
Boards Moderated | 0 |
Alias Born | 11/15/2006 |
Tuesday, November 23, 2021 8:58:41 AM
Recent KTTA News
- Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/29/2024 11:59:00 AM
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers • GlobeNewswire Inc. • 04/24/2024 11:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:23 AM
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 • GlobeNewswire Inc. • 02/13/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:30:41 PM
- Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position • GlobeNewswire Inc. • 01/08/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:47:43 PM
- Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients • GlobeNewswire Inc. • 01/02/2024 01:35:05 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/28/2023 10:00:30 PM
- Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 • GlobeNewswire Inc. • 12/28/2023 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 04:30:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/19/2023 10:26:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:21:07 PM
- Pasithea Therapeutics Announces Results from 2023 Annual Meeting • GlobeNewswire Inc. • 12/19/2023 10:19:00 PM
- Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models • GlobeNewswire Inc. • 12/11/2023 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/29/2023 10:00:00 PM
- Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders • GlobeNewswire Inc. • 11/29/2023 09:27:00 PM
- Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development • GlobeNewswire Inc. • 11/29/2023 12:59:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM